CoChat

Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants

Collins, Carmel T., Makrides, Maria, McPhee, Andrew J., Sullivan, Thomas R., Davis, Peter G., Thio, Marta, Simmer, Karen, Rajadurai, Victor S., Travadi, Javeed, Berry, Mary J., Liley, Helen G., Opie, Gillian F., Tan, Kenneth, Lui, Kei, Morris, Scott A., Stack, Jacqueline, Stark, Michael J., Chua, Mei-Chien, Jayagobi, Pooja A., Holberton, James, Bolisetty, Srinivas, Callander, Ian R., Harris, Deborah L., Gibson, Robert A. · 2017 · New England Journal of Medicine
Cited by 175

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Studies in animals and in humans have suggested that docosahexaenoic acid (DHA), an n-3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriately designed trials are lacking. METHODS: We randomly assigned 1273 infants born before 29 weeks of gestation (stratified according to sex, gestational age [<27 weeks or 27 to <29 weeks], and center) within 3 days after their first enteral feeding to receive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without DHA until 36 weeks of postmenstrual age. The primary outcome was bronchopulmonary dysplasia, defined on a physiological basis (with the use of oxygen-saturation monitoring in selected infants), at 36 weeks of postmenstrual age or discharge home, whichever occurred first. RESULTS: A total of 1205 infants survived to the primary outcome assessment. Of the 592 infants assigned to the DHA group, 291 (49.1% by multiple imputation) were classified as having physiological bronchopulmonary dysplasia, as compared with 269 (43.9%) of the 613 infants assigned to the control group (relative risk adjusted for randomization strata, 1.13; 95% confidence interval [CI], 1.02 to 1.25; P=0.02). The composite outcome of physiological bronchopulmonary dysplasia or death before 36 weeks of postmenstrual age occurred in 52.3% of the infants in the DHA group and in 46.4% of the infants in the control group (adjusted relative risk, 1.11; 95% CI, 1.00 to 1.23; P=0.045). There were no significant differences between the two groups in the rates of death or any other neonatal illnesses. Bronchopulmonary dysplasia based on a clinical definition occurred in 53.2% of the infants in the DHA group and in 49.7% of the infants in the control group (P=0.06). CONCLUSIONS: Enteral DHA supplementation at a dose of 60 mg per kilogram per day did not result in a lower risk of physiological bronchopulmonary dysplasia than a control emulsion among preterm infants born before 29 weeks of gestation and may have resulted in a greater risk. (Funded by the Australian National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12612000503820 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1611942

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 175

Metadata

Authors
Collins, C. T., Makrides, M., McPhee, A. J., Sullivan, T. R., Davis, P. G., Thio, M., Simmer, K., Rajadurai, V. S., Travadi, J., Berry, M. J., Liley, H. G., Opie, G. F., Tan, K., Lui, K., Morris, S. A., Stack, J., Stark, M. J., Chua, M.-C., Jayagobi, P. A., Holberton, J., Bolisetty, S., Callander, I. R., Harris, D. L., & Gibson, R. A.
Venue
New England Journal of Medicine
Published
2017-03-30
Volume
376
Issue
13
Pages
1245-1255
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2603314970
Cited by
175
References
2
FWCI
11.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants. https://app.cochat.ai/papers/10.1056/nejmoa1611942
The paper
Collins, C. T., Makrides, M., McPhee, A. J., Sullivan, T. R., Davis, P. G., Thio, M., Simmer, K., Rajadurai, V. S., Travadi, J., Berry, M. J., Liley, H. G., Opie, G. F., Tan, K., Lui, K., Morris, S. A., Stack, J., Stark, M. J., Chua, M.-C., Jayagobi, P. A., . . . Gibson, R. A. (2017). Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1611942

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.